Soon Hin How
YOU?
Author Swipe
View article: Intermittent afatinib treatment suppresses the growth of resistant T790M-H1975 cells in non-small cell lung cancer (NSCLC) co-culture
Intermittent afatinib treatment suppresses the growth of resistant T790M-H1975 cells in non-small cell lung cancer (NSCLC) co-culture Open
Objectives Most non-small-cell lung cancers (NSCLC) that harbour an epidermal growth factor receptor (EGFR) mutation are treated with afatinib. Resistance emerges in most patients, making treatment ineffective. Reports suggest intermittent…
View article: Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA Open
Lazertinib demonstrated comparable efficacy and safety to osimertinib, including in predefined subgroups.
View article: Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset Open
Amivantamab-lazertinib demonstrated superior progression-free survival versus osimertinib in Asian participants, with a tolerable safety profile. These results were consistent with those in the overall population.
View article: 1461 Phase 2 randomized study of domvanalimab combined with zimberelimab in front-line, PD-(L)1 high, locally advanced or metastatic non-small cell lung cancer (NSCLC): results from ARC-10 part 1
1461 Phase 2 randomized study of domvanalimab combined with zimberelimab in front-line, PD-(L)1 high, locally advanced or metastatic non-small cell lung cancer (NSCLC): results from ARC-10 part 1 Open
View article: Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer Open
Treatment with low dose osimertinib demonstrated good efficacy and tolerability in EGFR-mutated advanced NSCLC patients who failed first-line treatment with first- or second-generation EGFR TKIs due to T790M mutation.
View article: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice? Open
Lower afatinib doses (EGFR-mutant advanced NSCLC and may be more suited to Asian patients, minimizing side effects that may occur at higher dosages of afatinib leading to dose interruptions and affecting treatment outcomes.
View article: 121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy
121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy Open
View article: P2.09-03 Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis
P2.09-03 Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis Open
View article: Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301 Open
In LASER301, efficacy and safety results in Asian patients were consistent with the overall population. Lazertinib exhibited better efficacy than gefitinib in Asian patients with a tolerable safety profile.
View article: Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 Open
PURPOSE Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients wit…
View article: Intermittent EGFR-TKI Therapy is Associated with Durable Response in Advanced EGFR-Mutant NSCLC: A Case Report
Intermittent EGFR-TKI Therapy is Associated with Durable Response in Advanced EGFR-Mutant NSCLC: A Case Report Open
Madam S, who diagnosed to have stage IV lung adenocarcinoma with exon 21 L858R point mutation (T3N2M1a) was admitted for massive pericardial effusion in April 2016. She was ECOG 4 on admission. Her ECOG improved to 1 after pericardial tapp…
View article: Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country Open
Patients on ALK inhibitors had longer median OS and significantly longer TOT compared to chemotherapy, suggesting long-term benefit.
View article: Application of Real-Time Cell Analysis Biosensor Technology for Drug Cytotoxicity Studies in Primary Lung Cancer Cells
Application of Real-Time Cell Analysis Biosensor Technology for Drug Cytotoxicity Studies in Primary Lung Cancer Cells Open
View article: Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia Open
In the real-world, the management of EGFRm+ advanced NSCLC patients in an Asian cost-restrictive setting may adversely affect the choice of first-line therapy, time on each line of treatment and subsequently the overall survival of …
View article: Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country
Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country Open
Introduction Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) expression is a recognized biomarker to determine response to therapy.…
View article: Hybrid de novo Whole-Genome Assembly and Annotation of SARS-CoV-2 Virus from Nosocomial Infection in Pahang, Malaysia
Hybrid de novo Whole-Genome Assembly and Annotation of SARS-CoV-2 Virus from Nosocomial Infection in Pahang, Malaysia Open
View article: Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression Open
Immunotherapy is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with high PDL-1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.
View article: Asymptomatic Coronavirus Disease 2019 (COVID-19) Carriers: Are They Infectious?
Asymptomatic Coronavirus Disease 2019 (COVID-19) Carriers: Are They Infectious? Open
Coronavirus disease 2019 (COVID-19) is highly contagious in symptomatic patients as it is thought to be transmitted through respiratory droplets. However, it is debatable whether asymptomatic COVID-19 patients are contagious due to lack of…
View article: Lung Cancer in Malaysia
Lung Cancer in Malaysia Open
View article: Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society Open
View article: Emerging respiratory infections threatening public health in the Asia‐Pacific region: A position paper of the Asian Pacific Society of Respirology
Emerging respiratory infections threatening public health in the Asia‐Pacific region: A position paper of the Asian Pacific Society of Respirology Open
In past decades, we have seen several epidemics of respiratory infections from newly emerging viruses, most of which originated in animals. These emerging infections, including severe acute respiratory syndrome coronavirus (SARS‐CoV), Midd…
View article: Depressive Symptoms in Newly Diagnosed Lung Carcinoma: Prevalence and Associated Risk Factors
Depressive Symptoms in Newly Diagnosed Lung Carcinoma: Prevalence and Associated Risk Factors Open
One in three of lung carcinoma patients, are at increased risk for depression. Clinicians should be aware that risk is highest in those with poor performance status, single, and with poor IR. We suggest routine screening of depression symp…